A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938
administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV
infection who are at high risk for complications after RSV infection.